These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 11464473

  • 41. [Multiple sclerosis].
    Itoyama Y.
    No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
    [No Abstract] [Full Text] [Related]

  • 42. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A.
    Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
    [Abstract] [Full Text] [Related]

  • 43. Future immunotherapies in multiple sclerosis.
    Blevins G, Martin R.
    Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380
    [Abstract] [Full Text] [Related]

  • 44. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET, Giovannoni G.
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [Abstract] [Full Text] [Related]

  • 45. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
    Biernacki K, Antel JP, Blain M, Narayanan S, Arnold DL, Prat A.
    Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
    [Abstract] [Full Text] [Related]

  • 46. Current concepts in multiple sclerosis: Part II.
    Hanson LJ, Cafruny WA.
    S D J Med; 2002 Nov; 55(11):477-81. PubMed ID: 12449589
    [Abstract] [Full Text] [Related]

  • 47. Immunotherapy of multiple sclerosis.
    Weiner HL, Hafler DA.
    Ann Neurol; 1988 Mar; 23(3):211-22. PubMed ID: 3288084
    [Abstract] [Full Text] [Related]

  • 48. How should we proceed with disease-modifying treatments for multiple sclerosis?
    Andersson PB, Waubant E, Goodkin DE.
    Lancet; 1997 Mar 01; 349(9052):586-7. PubMed ID: 9057726
    [No Abstract] [Full Text] [Related]

  • 49. Multiple sclerosis. II. A critical assessment of immunotherapy.
    Durelli L, Bergamini L.
    Riv Neurol; 1989 Mar 01; 59(5):191-201. PubMed ID: 2483962
    [Abstract] [Full Text] [Related]

  • 50. Vaccines for multiple sclerosis: progress to date.
    Correale J, Farez M, Gilmore W.
    CNS Drugs; 2008 Mar 01; 22(3):175-98. PubMed ID: 18278975
    [Abstract] [Full Text] [Related]

  • 51. [Causal therapy of multiple sclerosis].
    Pöhlau D, Rieks M, Postert T, Hoffmann V, Przuntek H.
    Dtsch Med Wochenschr; 1996 Nov 08; 121(45):1407-14. PubMed ID: 8964231
    [No Abstract] [Full Text] [Related]

  • 52. Immunotherapeutics of multiple sclerosis.
    Durelli L.
    Acta Neurol (Napoli); 1991 Oct 08; 13(5):467-75. PubMed ID: 1723242
    [Abstract] [Full Text] [Related]

  • 53. Tovaxin for multiple sclerosis.
    Rivera VM.
    Expert Opin Biol Ther; 2011 Jul 08; 11(7):961-7. PubMed ID: 21563876
    [Abstract] [Full Text] [Related]

  • 54. [Cytokines slow down the progression of MS. Successful animal experiments with a vaccine].
    Orn P.
    Lakartidningen; 1996 Feb 14; 93(7):573-5. PubMed ID: 8642918
    [No Abstract] [Full Text] [Related]

  • 55. [Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy].
    Soukop W, Tschabitscher H.
    Wien Med Wochenschr; 1986 Sep 30; 136(18):477-80. PubMed ID: 2948324
    [Abstract] [Full Text] [Related]

  • 56. Treatment of multiple sclerosis in children and adolescents.
    Kuntz NL, Chabas D, Weinstock-Guttman B, Chitnis T, Yeh EA, Krupp L, Ness J, Rodriguez M, Waubant E, Network of US Pediatric Multiple Sclerosis Centers.
    Expert Opin Pharmacother; 2010 Mar 30; 11(4):505-20. PubMed ID: 20163265
    [Abstract] [Full Text] [Related]

  • 57. Overview of the rationale for immunomodulating therapies in multiple sclerosis.
    Lisak RP.
    Neurology; 1988 Jul 30; 38(7 Suppl 2):5-8. PubMed ID: 3290714
    [Abstract] [Full Text] [Related]

  • 58. Immunological basis for the therapy of multiple sclerosis.
    Hohlfeld R.
    Acta Neurol Belg; 1999 Mar 30; 99(1):40-3. PubMed ID: 10218091
    [Abstract] [Full Text] [Related]

  • 59. [Treatment of multiple sclerosis].
    Fernández Uría D.
    Neurologia; 1999 Dec 30; 14 Suppl 6():1-12. PubMed ID: 10659600
    [Abstract] [Full Text] [Related]

  • 60. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
    Wiendl H, Hohlfeld R.
    BioDrugs; 2002 Dec 30; 16(3):183-200. PubMed ID: 12102646
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.